-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A high tumor mutational burden (TMB-H) was associated with elevated neoantigen expression in tumors and increased response to PD-(L)1 inhibitors
A high tumor mutational burden (TMB-H) was associated with elevated neoantigen expression in tumors and increased response to PD-(L)1 inhibitors
The trial enrolled patients with various solid tumors (pts) and treated them with tislelizumab (NCT02407990)
451 patients were enrolled and treated with different doses of tislelizumab
451 patients were enrolled and treated with different doses of tislelizumab
The results showed that the overall objective response rate of patients was 13.
Table: Clinical outcomes of pts subgroups by TMB and HA status
Further, the trial results were validated in an independent PD-(L)1 inhibitor-treated pan-cancer cohort (n=837)
Further, the trial results were validated in an independent PD-(L)1 inhibitor-treated pan-cancer cohort (n=837)
This study found that the combination of TMB and HA was predictive of clinical benefit with tislelizumab in various solid tumor types
source:
source:https://#!/10517/presentation/19966
https://#!/10517/presentation/19966 https://#!/10517/presentation/19966Leave a message here